Drugs / Cancer vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01081223 | Apr 2010 → Mar 2011 | glioblastoma | TVAX Biomedical | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-08-04 | Abogen Biosciences Co. Ltd. | Regulatory Abogen Received Dual IND Approvals for KRAS mRNA Vaccine in China and the United States abogenbio.com ↗
On August 4, 2025, Abogen Biosciences announced that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) granted Investigational New Drug (IND) approval for its novel KRAS mRNA cancer vaccine ABO2102, targeting five common mutations. |
| 2025-05-14 | Abogen Biosciences Co. Ltd. | Regulatory Abogen Received FDA IND Approval for KRAS mRNA Vaccine abogenbio.com ↗
On May 9, 2025, Abogen Biosciences announced that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) approval for its novel KRAS mRNA cancer vaccine ABO2102, targeting five common KRAS mutations. |
| 2024-09-19 | BioNet-Asia Co., Ltd. | Results A new way to reprogram immune cells and direct them toward anti-tumor immunity bionet-asia.com ↗
This work presents a strategy for targeting those antigens to the dendritic cells that results in a more activated, stronger immune response. |
| 2024-04-10 | Tallac Therapeutics | Results Tallac Therapeutics Presents New Preclinical Data on TAC-001 in Combination with Cancer Vaccines at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) tallactherapeutics.com ↗
Tallac Therapeutics, Inc., a privately held clinical stage biopharmaceutical company pioneering the discovery and development of novel antibody-oligonucleotide conjugates, today announced the presentation of preclinical data demonstrating TAC-001 potentiates cancer vaccine efficacy and rejuvenates vaccine responses. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-08-04 | Abogen Biosciences Co. Ltd. | Abogen Received Dual IND Approvals for KRAS mRNA Vaccine in China and the United States abogenbio.com ↗ |
| 2025-05-14 | Abogen Biosciences Co. Ltd. | Abogen Received FDA IND Approval for KRAS mRNA Vaccine abogenbio.com ↗ |
| 2024-09-19 | BioNet-Asia Co., Ltd. | A new way to reprogram immune cells and direct them toward anti-tumor immunity bionet-asia.com ↗ |
| 2024-04-10 | Tallac Therapeutics | Tallac Therapeutics Presents New Preclinical Data on TAC-001 in Combination with Cancer Vaccines at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) tallactherapeutics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cancer vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01081223 ↗ |
| Modality | Vaccine | “Tumor tissue is used for cancer vaccine.” NCT01081223 ↗ |